糖尿病冠脉支架术后长期维持:氯吡格雷优于阿司匹林(HOST-EXAM事后分析)
该研究为HOST-EXAM随机试验的事后分析,纳入5438例药物洗脱支架术后完成6-18个月双联抗血小板治疗且无事件的患者,其中1860例(34.2%)有糖尿病。随访24个月,糖尿病患者的首要复合终点(全因死亡、非致死性心梗、卒中、ACS再入院、BARC 3或5型大出血)氯吡格雷组显著低于阿司匹林组(6.3% vs 9.2%;HR 0.69;95%CI 0.49-0.96;HR 0.76;95%CI 0.58-1.00;
要点
- 糖尿病合并冠心病支架术后完成双抗者,氯吡格雷单药较阿司匹林降低24个月复合终点风险。
- 糖尿病患者氯吡格雷组绝对风险降低2.7%,NNT=37;无糖尿病者ARD 1.6%,NNT=63。
- 糖尿病状态未显著改变氯吡格雷的获益(交互作用P=0.65)。
核心结论
- 在糖尿病及非糖尿病患者中,氯吡格雷单药作为支架术后双抗后的长期维持治疗,首要复合终点发生率均低于阿司匹林单药。
- 无论糖尿病状态,冠脉支架术后成功完成双抗治疗者,可考虑选用氯吡格雷而非阿司匹林。
研究设计与样本
- HOST-EXAM随机临床试验的事后分析,研究者发起、前瞻性、随机、开放标签、多中心试验,韩国37个中心。
- 纳入2014年3月至2018年5月药物洗脱支架PCI后接受双联抗血小板治疗6-18个月无临床事件的患者,共5438例,按1:1随机分配至氯吡格雷或阿司匹林单药,随访至24个月。
- 平均(SD)年龄63.5(10.7)岁,女性1384例(25.5%),糖尿病1860例(34.2%;氯吡格雷组925例,阿司匹林组935例),5338例(98.2%)完成随访。
- 事后分析执行于2021年6月至10月。
关键数值与推荐
- 首要复合终点定义:24个月随访时全因死亡、非致死性心肌梗死、卒中、因急性冠脉综合征再入院及BARC 3或5型大出血的复合终点。
- 糖尿病亚组首要终点绝对风险差2.7%,需治疗人数37;无糖尿病亚组绝对风险差1.6%,需治疗人数63。
临床怎么用
- 对于药物洗脱支架PCI后已完成6-18个月双联抗血小板治疗且无临床事件的患者,无论是否合并糖尿病,可优先考虑氯吡格雷单药而非阿司匹林进行长期维持。
- 糖尿病患者的绝对获益幅度更大(NNT 37 vs 63),支持在该人群中更积极选用氯吡格雷。
局限性
- 本研究为HOST-EXAM试验的事后分析,亚组结果需谨慎解读。
- 开放标签设计可能引入偏倚。
- 仅纳入韩国人群,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Selecting the optimal antiplatelet agent in patients who have received percutaneous coronary intervention is especially important in those with diabetes due to the heightened risk of ischemic events in this population. Studies on the efficacy and safety of clopidogrel vs aspirin for long-term maintenance after percutaneous coronary intervention in patients with diabetes are lacking. OBJECTIVE: To investigate cardiovascular outcomes with clopidogrel vs aspirin in patients with and without diabetes. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the HOST-EXAM randomized clinical trial, an investigator-initiated, prospective, randomized, open-label, multicenter trial performed at 37 centers in Korea. Patients who received dual antiplatelet therapy without clinical events for 6 to 18 months after percutaneous coronary intervention with drug-eluting stents were enrolled from March 2014 to May 2018 with follow-up at 6, 12, 18, and 24 months. All 5438 patients in the original trial were included in this analysis, which was conducted from June to October 2021. INTERVENTIONS AND EXPOSURES: Enrolled patients were randomized 1:1 to clopidogrel or aspirin monotherapy. Subgroup analyses were performed by the presence of diabetes. MAIN OUTCOMES AND MEASURES: The main outcome was primary composite end point of all-cause death, nonfatal myocardial infarction, stroke, readmission due to acute coronary syndrome, and major bleeding (Bleeding Academic Research Consortium type 3 or 5) at 24-month follow-up. RESULTS: Of 5438 patients (mean [SD] age, 63.5 [10.7] years; 1384 [25.5%] female), 1860 (34.2%) had diabetes (925 in the clopidogrel arm and 935 in the aspirin arm), and 5338 (98.2%) completed follow-up. The rate of the primary composite end point was significantly lower in the clopidogrel group compared to the aspirin group in patients with diabetes (6.3% vs 9.2%; hazard ratio [HR], 0.69; 95% CI, 0.49-0.96; P = .03; absolute risk difference [ARD], 2.7%; number needed to treat [NNT], 37) and without diabetes (5.3% vs 7.0%; HR, 0.76; 95% CI, 0.58-1.00; P = .046; ARD, 1.6%, NNT, 63; P for interaction = .65). The presence of diabetes was not associated with a difference in benefit observed with clopidogrel monotherapy over aspirin for the thrombotic composite end point (HR, 0.68; 95% CI, 0.45-1.04 for patients with diabetes vs HR, 0.68; 95% CI, 0.49-0.93 for those without; P for interaction = .99) and any bleeding with Bleeding Academic Research Consortium 2, 3, or 5 (HR, 0.65; 95% CI, 0.39-1.09 for patients with diabetes vs HR, 0.74; 95% CI, 0.48-1.13 for those without; P for interaction = .71). CONCLUSION AND RELEVANCE: In this study, clopidogrel monotherapy was associated with a lower rate of the primary composite end point compared to aspirin monotherapy as long-term maintenance therapy after dual antiplatelet therapy for coronary stenting in both patients with and without diabetes. Clopidogrel might thus be considered rather than aspirin in patients who have undergone coronary stenting and successfully completed dual antiplatelet therapy, regardless of diabetes status. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02044250.
引用
- Rhee, Bae, Park, et al. Aspirin vs Clopidogrel for Long-term Maintenance After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the HOST-EXAM Trial. JAMA Cardiol. 2023. PMID: 37043192. doi:10.1001/jamacardio.2023.0592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。